| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,207 |
3,733 |
$240K |
| 99285 |
|
1,511 |
1,399 |
$180K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,739 |
2,442 |
$63K |
| 99284 |
|
303 |
282 |
$34K |
| 0002A |
|
368 |
354 |
$32K |
| 0001A |
|
347 |
335 |
$31K |
| 96361 |
|
70 |
64 |
$20K |
| 99283 |
|
106 |
102 |
$12K |
| 80048 |
|
1,591 |
1,483 |
$9K |
| 86769 |
|
230 |
217 |
$9K |
| 0012A |
|
103 |
96 |
$9K |
| 80053 |
|
505 |
428 |
$7K |
| 85025 |
|
3,268 |
3,029 |
$3K |
| 84443 |
|
208 |
203 |
$2K |
| 36415 |
|
446 |
418 |
$1K |
| 0241U |
|
14 |
13 |
$839.07 |
| 84484 |
|
27 |
24 |
$502.77 |
| 80047 |
|
16 |
16 |
$364.90 |
| 96374 |
|
421 |
390 |
$345.55 |
| 93005 |
|
288 |
251 |
$251.26 |
| 80061 |
|
63 |
62 |
$229.90 |
| 84439 |
|
31 |
31 |
$216.45 |
| 83036 |
|
52 |
52 |
$193.04 |
| 81001 |
|
73 |
66 |
$112.46 |
| 85027 |
|
30 |
25 |
$69.00 |
| J3490 |
Unclassified drugs |
1,066 |
599 |
$47.80 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
38 |
37 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
65 |
64 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
18 |
12 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
179 |
91 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
16 |
15 |
$0.00 |
| 96375 |
|
73 |
61 |
$0.00 |